Clinical Trials for Galecto Biotech

Explore 4 clinical trials worldwide

Showing 1-4 of 4 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Galecto Biotech

Clinical Trials (4)

NCT07084584
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
PHASE1/PHASE2Not yet recruiting
184 participants
Started: Jun 10, 2026 · Completed: Oct 10, 2029
1 condition1 sponsor0 locations
NCT05913388
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
PHASE2Recruiting
92 participants
Started: Feb 29, 2024 · Completed: Feb 28, 2030
2 conditions4 sponsors1 location
NCT05240131
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
PHASE1/PHASE2Active, not recruiting
88 participants
Started: Mar 15, 2022 · Completed: Nov 1, 2025
1 condition3 sponsors5 locations
NCT04679870
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
PHASE2Active, not recruiting
21 participants
Started: Jun 9, 2021 · Completed: Jun 30, 2026
1 condition2 sponsors11 locations